Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The Publisher regrets that this article is an accidental duplication of an article that has already been published, http://dx.doi.org/10.1016/j.biomag.2010.12.001 The duplicate article has therefore been withdrawn.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biopha.2010.12.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Retraction notice to "Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation" [Eur. J. Pharmacol 483 (1) (2004) 79-93].
Eur J Pharmacol
November 2024
Department of Experimental Medicine and Nephrology, The William Harvey Research Institute, St. Bartholomew's and The Royal London School of Medicine and Dentistry, Charterhouse Square, London, EC1M 6BQ, UK.
Retraction Note: Rosiglitazone Inhibits Activation of Hepatic Stellate Cells via Up-Regulating Micro-RNA-124-3p to Alleviate Hepatic Fibrosis.
Dig Dis Sci
May 2023
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Wenzhou Medical University, 205 Wenrui Avenue, Wenzhou, 325000, People's Republic of China.
Rosiglitazone Alleviates Contrast-Induced Acute Kidney Injury in Rats via the PPAR/NLRP3 Signaling Pathway.
Dis Markers
October 2022
Department of Cardiology, Fujian Medical University Union Hospital, Fuzhou, 350001 Fujian, China.
Background: This study investigated the effect and mechanism of rosiglitazone on a rat model with contrast-induced acute kidney injury (CI-AKI).
Materials And Methods: The CI-AKI rat model was established from Sprague Dawley rats by furosemide injection (10 ml/kg) to the caudal vein followed by iohexol (11.7 ml/kg).